Role Definition
| Field | Value |
|---|---|
| Job Title | Regulatory Affairs Engineer — Medical Devices |
| Seniority Level | Mid-Senior |
| Primary Function | Develops and executes regulatory strategies for medical devices through FDA (510(k), PMA, De Novo), EU MDR, and global pathways. Prepares and manages regulatory submissions, interprets evolving guidance, maintains design control documentation, negotiates with regulators, and ensures post-market compliance. Sits at the intersection of engineering, quality, and regulatory science. |
| What This Role Is NOT | NOT a generic Regulatory Affairs Specialist (broader industry, weaker barriers, AIJRI 29.2). NOT a Compliance Officer (enforcement-focused). NOT a Quality Engineer (process-focused). NOT a Biomedical Engineer (design-focused, AIJRI 38.4). |
| Typical Experience | 5-10 years. BS/MS in biomedical or related engineering. RAC (Regulatory Affairs Certification) common. Deep knowledge of FDA 21 CFR 820, ISO 13485, EU MDR 2017/745, and increasingly FDA SaMD/AI-ML guidance. |
Seniority note: Junior regulatory associates performing documentation-only work would score deeper Yellow (closer to the generic Regulatory Affairs Specialist at 29.2). Senior/VP regulatory leaders setting global regulatory strategy and bearing personal submission accountability would score Green (Transforming).
Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 0 | Fully desk-based. No physical component to the core regulatory work. |
| Deep Interpersonal Connection | 1 | Regular professional relationships with FDA reviewers, notified bodies, and cross-functional teams. Trust matters in agency interactions but relationships are professional, not vulnerability-based. |
| Goal-Setting & Moral Judgment | 2 | Significant judgment calls on regulatory pathway selection, risk-benefit interpretation, and whether devices meet safety/efficacy standards. Defines what "adequate evidence" means for novel devices. Not pure rule-following — requires interpretation of ambiguous, evolving guidance. |
| Protective Total | 3/9 | |
| AI Growth Correlation | 1 | AI-enabled medical devices (950+ FDA-cleared by late 2025) are creating new regulatory complexity — PCCP plans, SaMD lifecycle management, algorithmic bias controls. Demand grows with AI adoption in medtech, but the role predates AI. |
Quick screen result: Protective 3/9 with weak positive correlation — likely Yellow Zone.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| Regulatory strategy & pathway development | 20% | 2 | 0.40 | AUGMENTATION | Core strategic judgment — choosing 510(k) vs PMA vs De Novo, global sequencing, predicate selection. AI can model scenarios but the engineer owns the decision and bears accountability for pathway choices that affect years of development. |
| Regulatory submission preparation (510(k)/PMA/De Novo) | 20% | 3 | 0.60 | AUGMENTATION | AI tools draft substantial sections, compile predicate comparisons, and auto-populate eSTAR templates. Engineer still leads content strategy, validates technical claims, and ensures clinical evidence adequacy. Human-led but AI handles significant sub-workflows. |
| Regulatory intelligence & standards interpretation | 15% | 3 | 0.45 | AUGMENTATION | AI monitors regulatory changes globally, summarises guidance, and flags impacts. Engineer interprets ambiguous guidance for specific device contexts and novel technologies — judgment AI cannot reliably provide. |
| Design control & DHF review | 15% | 3 | 0.45 | AUGMENTATION | AI performs gap analysis across design history files, cross-references requirements. Engineer validates completeness, interprets whether risk controls are adequate, and ensures traceability of design decisions. |
| Agency interactions & negotiations | 10% | 1 | 0.10 | NOT INVOLVED | Pre-submission meetings, responding to FDA questions, negotiating testing requirements. Entirely human — requires persuasion, credibility, and real-time interpretation of reviewer concerns. No AI substitute. |
| Post-market surveillance & compliance monitoring | 10% | 4 | 0.40 | DISPLACEMENT | AI agents can monitor adverse event databases (MAUDE), generate periodic safety reports, track complaint trends, and flag signals. Human reviews output but agent executes the bulk workflow. |
| Cross-functional collaboration (R&D, QA, clinical) | 5% | 2 | 0.10 | AUGMENTATION | Coordinating regulatory requirements into design and manufacturing. Requires organisational navigation, influence, and context that AI cannot replace. |
| Regulatory documentation & technical writing | 5% | 4 | 0.20 | DISPLACEMENT | Drafting SOPs, regulatory procedures, labelling content. AI tools already generate compliant documentation from templates and prior submissions. |
| Total | 100% | 2.70 |
Task Resistance Score: 6.00 - 2.70 = 3.30/5.0
Displacement/Augmentation split: 15% displacement, 75% augmentation, 10% not involved.
Reinstatement check (Acemoglu): AI creates significant new tasks — validating AI-generated submission content, developing PCCP (Predetermined Change Control Plans) for AI/ML devices, interpreting FDA's evolving SaMD guidance, auditing AI tool outputs for regulatory accuracy, and managing the regulatory lifecycle of adaptive AI algorithms. The role is expanding into AI-specific regulatory territory.
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | 1 | Indeed shows active demand for medical device regulatory affairs with AI skills. Nearly 70% of regulatory employers plan to increase AI integration by 2026 (Research.com). Growing faster than the generic regulatory affairs market due to AI-device proliferation. |
| Company Actions | 1 | No companies cutting regulatory affairs citing AI. Medtronic, J&J, Abbott, Boston Scientific, Meta all actively hiring regulatory affairs professionals for medical devices. FDA cleared 950+ AI/ML devices by late 2025 — each requiring regulatory oversight. |
| Wage Trends | 1 | Senior regulatory affairs engineers command $100,000-$180,000 (Glassdoor, Salary.com). AI-skilled regulatory professionals commanding premium. Real growth above inflation driven by demand for SaMD/AI-ML regulatory expertise. |
| AI Tool Maturity | -1 | AI tools automating predicate analysis, submission drafting (eSTAR auto-population), regulatory intelligence monitoring, and post-market surveillance. Intuition Labs, Jama Software, and MasterControl deploying AI-assisted regulatory workflows. In early-to-mid adoption — automating 30-40% of documentation workflows but not displacing headcount yet. |
| Expert Consensus | 1 | RAPS, AdvaMed, and industry analysts unanimously predict augmentation not displacement. IQVIA white paper (2025) confirms AI strengthens QA/RA roles. No credible source predicts regulatory affairs displacement — rising complexity from AI device regulation creates more work, not less. |
| Total | 3 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 2 | FDA 510(k)/PMA submissions require human sign-off. EU MDR mandates qualified Person Responsible for Regulatory Compliance (PRRC). RAC certification standard. FDA's 2025 SaMD guidance explicitly requires human accountability for AI-enabled device submissions. EU AI Act classifies medical AI as high-risk requiring human oversight. |
| Physical Presence | 0 | Fully remote/digital. No physical component. |
| Union/Collective Bargaining | 0 | No union representation in regulatory affairs engineering. |
| Liability/Accountability | 2 | Medical device regulatory submissions carry personal and corporate liability. Misrepresentation to FDA is criminal (21 USC 331). Device failures traced to inadequate regulatory submissions result in corporate fines, product recalls, and personal accountability. AI has no legal personhood — a human must sign and be accountable. |
| Cultural/Ethical | 1 | Moderate cultural resistance to AI-authored regulatory submissions for devices implanted in or used on humans. FDA reviewers expect human professionals behind submissions. Patient safety demands human accountability chain. |
| Total | 5/10 |
AI Growth Correlation Check
Confirmed +1 (Weak Positive). The proliferation of AI-enabled medical devices (950+ FDA-cleared by late 2025, 30-40% CAGR) directly creates new regulatory work — PCCP plans, SaMD lifecycle management, algorithmic bias documentation, cybersecurity requirements. However, the role is not AI-created — it existed long before AI in medtech. The growth is incremental demand layered on top of existing device regulation, not a new role category.
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 3.30/5.0 |
| Evidence Modifier | 1.0 + (3 x 0.04) = 1.12 |
| Barrier Modifier | 1.0 + (5 x 0.02) = 1.10 |
| Growth Modifier | 1.0 + (1 x 0.05) = 1.05 |
Raw: 3.30 x 1.12 x 1.10 x 1.05 = 4.27
JobZone Score: (4.27 - 0.54) / 7.93 x 100 = 47.0/100
Zone: YELLOW (Yellow 25-47)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 65% |
| AI Growth Correlation | 1 |
| Sub-label | Yellow (Urgent) — AIJRI 25-47 AND 65% >= 40% of task time scores 3+ |
Assessor override: None — formula score accepted. The 47.0 is 1 point below the Green threshold. This borderline position is honest: the role has strong barriers and positive evidence, but 65% of task time faces meaningful AI automation (score 3+), and the task resistance of 3.30 reflects real exposure in submission preparation, regulatory intelligence, and documentation. The barriers prevent displacement but do not prevent transformation.
Assessor Commentary
Score vs Reality Check
The 47.0 score places this role 1 point below the Green Zone boundary — the most borderline Yellow assessment in the engineering domain. This is barrier-dependent: without the 5/10 barriers (FDA human mandate, criminal liability), the score would drop to approximately 40.5. The barriers are structural and strengthening — FDA's SaMD guidance is adding requirements, not removing them — so this dependency is well-founded. The borderline position reflects a genuine tension: the core judgment work is resistant, but the volume of automatable sub-tasks (documentation, surveillance, intelligence gathering) is substantial.
What the Numbers Don't Capture
- Bimodal distribution — Regulatory affairs engineers specialising in AI/ML devices and SaMD are experiencing demand growth that the average score understates. Those focused on traditional Class I/II devices with well-established predicates face more automation pressure as AI can handle routine submissions more independently.
- Title rotation — "Regulatory Affairs Engineer" is increasingly being posted as "AI Regulatory Specialist" or "Digital Health Regulatory Lead" at forward-looking medtech companies. The function grows while the traditional title may plateau.
- Regulatory complexity as a moat — Each new FDA guidance, EU MDR deadline, and AI Act requirement adds interpretive work that cannot be automated. The increasing pace of regulatory change (QMSR enforcement Feb 2026, EU MDR May 2026, new AI/ML guidance forthcoming) works in this role's favour.
Who Should Worry (and Who Shouldn't)
If you are a mid-senior regulatory affairs engineer who understands AI/ML device regulation, can navigate PCCP submissions, and regularly negotiates with FDA reviewers in pre-submission meetings, you are safer than this label suggests — likely operating at a functional Green level. If you are primarily compiling 510(k) submissions from templates, tracking regulatory changes without interpreting them, or producing documentation without strategic input, the automation wave is heading directly for your daily tasks. The single biggest differentiator is whether you make regulatory decisions or execute regulatory processes — decision-makers are protected by irreducible accountability barriers; process executors are vulnerable to AI agents.
What This Means
The role in 2028: The surviving mid-senior regulatory affairs engineer is a strategic regulatory navigator who uses AI tools to monitor global regulatory landscapes, auto-generate first-draft submissions, and flag compliance signals — then applies judgment to interpret ambiguous guidance, negotiate with regulators, and make risk-benefit decisions that carry personal accountability. Pure documentation work is automated.
Survival strategy:
- Specialise in AI/ML medical device regulation — PCCP development, SaMD lifecycle management, FDA's evolving AI guidance, EU AI Act compliance for high-risk medical AI
- Build direct agency relationships — pre-submission meetings, reviewer interactions, and notified body negotiations are irreducibly human and the most protected part of the role
- Master AI-assisted regulatory tools — become the person who directs AI drafting workflows and validates AI-generated submission content, not the person whose work AI replaces
Where to look next. If you're considering a career shift, these Green Zone roles share transferable skills with regulatory affairs engineering:
- Medical Device Software Engineer (Mid-Senior) (AIJRI 54.5) — regulatory knowledge of SaMD transfers directly to the technical development side
- AI Auditor (Mid) (AIJRI 64.5) — regulatory compliance and quality system expertise maps to auditing AI systems
- Compliance Manager (AIJRI 53.1) — regulatory strategy and agency interaction skills transfer to broader compliance leadership
Browse all scored roles at jobzonerisk.com to find the right fit for your skills and interests.
Timeline: 3-5 years. FDA regulation provides structural protection, but AI submission tools are advancing rapidly. The transformation window is compressed by the pace of AI tool maturity in RegTech.
